
Senores Pharmaceuticals Limited witnessed its shares surge over 8% to ₹538.65 on Tuesday, January 23, following the announcement of its robust Q3 FY25 financial results. The company reported strong growth across key metrics, showcasing its operational efficiency and strategic progress.
Key Financial Highlights (Q3 FY25 vs Q3 FY24):
- Revenue from Operations: ₹103.02 crore, marking a 31% YoY increase from ₹78.70 crore.
- Total Income: ₹108.17 crore, up 36% YoY from ₹79.50 crore.
- Profit Before Tax (PBT): ₹20.48 crore, a significant 99% increase from ₹10.26 crore.
- Net Profit (PAT): ₹16.43 crore, reflecting a stellar 131% YoY rise from ₹7.11 crore.
Nine-Month Financial Highlights (9M FY25 vs 9M FY24):
- Revenue from Operations: ₹284.04 crore, a 33% growth compared to ₹214.52 crore.
- Net Profit: ₹40.37 crore, a notable 19% YoY rise from ₹32.71 crore.
Operational Updates:
The impressive performance is attributed to efficient cost management, higher demand for its pharmaceutical products, and strategic operational measures. The total expenses for Q3 FY25 increased to ₹87.69 crore, up from ₹69.25 crore in Q3 FY24, driven by higher material costs and employee benefit expenses.
SENORES PHARMACEUTICALS L Share Price history
Day | Open | Close | Change % |
---|---|---|---|
Wed, Jan 22 2025
|
₹510.00
|
₹498.50
|
-2.28%
|
Tue, Jan 21 2025
|
₹528.00
|
₹510.15
|
-2.88%
|
Mon, Jan 20 2025
|
₹530.00
|
₹525.30
|
-0.02%
|
Fri, Jan 17 2025
|
₹509.10
|
₹525.40
|
|
Thu, Jan 16 2025
|
₹477.60
|
₹510.80
|
|
Wed, Jan 15 2025
|
₹472.20
|
₹470.50
|
|
Tue, Jan 14 2025
|
₹446.15
|
₹464.75
|
|
Mon, Jan 13 2025
|
₹494.20
|
₹444.30
|
-11.64%
|